Abstract
Cannabidiol (CBD) product regulatory efforts must be informed by research regarding consumer perceptions. This mixed-methods study examined CBD product information sources, knowledge, perceptions, use and use intentions among young adults. This study analyzed (i) Fall 2020 survey data from 2464 US young adults (Mage = 24.67, 51.4% ever users, 32.0% past 6-month users) and (ii) Spring 2021 qualitative interviews among 40 survey participants (27.5% past-month users). Overall, 97.9% of survey participants reported having heard of CBD, 51.4% ever/lifetime use and 32.0% past 6-month use. Survey participants learned about CBD from friends/family (58.9%), products/ads at retailers (36.4%), online content/ads (34.8%), CBD stores (27.5%) and social media (26.7%). One-fourth believed that CBD products were required to be US Food and Drug Administration-approved (24.9%), tested for safety (28.8%) and proven effective to be marketed for pain, anxiety, sleep, etc. (27.2%). Survey and interview participants perceived CBD as safe, socially acceptable and effective for addressing pain, anxiety and sleep. Interview findings expanded on prominent sources of marketing and product exposure, including online and specialty retailers (e.g. vape shops), and on participants’ concerns regarding limited regulation and/or evidence regarding CBD’s effectiveness/risks. Given young adults’ misperceptions about CBD, surveillance of CBD knowledge, perceptions and use is critical as the CBD market expands.
Introduction
The Agriculture Improvement Act of 2018 (i.e. the Farm Bill) allowed cannabis derivatives containing ≤0.3% tetrahydrocannabinol (THC) to be excluded from the category of federally controlled substances [1–3]. Since then, there has been rapid popularization of products containing cannabidiol (CBD) [4, 5], one of the main active cannabinoids of the cannabis plant. CBD, which does not have the psychoactive properties of THC [6], is advertised as a food and health supplement [7]. In 2019, over 25% of US adults reported ever trying CBD products at least once in the past 2 years [8] and ∼14% reported ‘personally using’ CBD products [9]. CBD use is particularly prominent among those aged 18–29 years, with 2019 reports indicating 39.7% ever used in their lifetime [8, 10], 40% used at least once in the past 2 years [8] and 20% ‘personally use’ CBD products [9].
Many types of retailers sell CBD products, including pharmacies, gas stations, convenience stores, health/vitamin shops and coffee shops [6, 11–14]. CBD is typically consumed as pills, edibles or beverages [15], but can also be vaped, applied topically (e.g. oils and lotions) and used in other ways [12, 16–18]. Among young-adult CBD users, edibles, tinctures and vape products were most commonly used for stress relief, relaxation and sleep [10, 18].
Recent evidence has shown that people hold positive perceptions of CBD despite having limited knowledge of its evidence base or regulation [10, 19]. In one study of US adult CBD users, 75.9% of respondents reported learning about CBD from internet research, family members or friends [20]. A social media analysis of Pinterest indicated that pins portrayed an overall positive view of CBD use for health promotion but failed to provide reliable sources and contained limited information regarding US Food and Drug Administration (FDA) regulation, dosage or side effects [21]. The same study found that 42% of pins endorsed CBD use for treating problems with mental or physical health, which is concerning given that social media communications are outside of the purview of FDA regulation [21].
However, the FDA has not yet approved CBD-based treatments for conditions other than epilepsy (i.e. Epidiolex [11, 22]), even though CBD use has been associated with significant improvements in conditions such as psychotic symptoms, anxiety, seizures, pain and Crohn’s disease [23, 24]. This is especially important given that people have limited knowledge of CBD’s evidence base or regulation [10, 19] and are often exposed to unreliable sources of information [21], particularly via the internet, which is among the most common sources of information [20].
As CBD product marketing and product use increase, there is also an increased need to enhance the evidence base informing its regulatory oversight. Such regulatory oversight is critical [25], as indicated by recent legislation that includes three bills introduced by the US Congress in 2021 [26–28] and several state efforts to regulate CBD product retail, marketing, packaging and labeling [25]. Such regulatory efforts must be informed by research regarding CBD use, perceptions and correlates of use and intentions to use. This is particularly relevant among young adults who represent a group especially likely to use CBD [8–10]. Unfortunately, the existing literature is limited by relatively small sample sizes, limited geographic diversity and assessments limited in scope (i.e. few survey items and only closed-ended questions), among other limitations [6, 10, 18, 20].
Thus, this paper adds to the evidence base regarding CBD perceptions and use among a large sample of young adults across the United States, using a mixed-methods design with comprehensive quantitative and qualitative assessments. More specifically, this study used data from surveys and semi-structured interviews to examine CBD product information sources, knowledge, perceptions, use and use intentions among young adults.
Methods
This study analyzed data among young adults (ages 18–34) in a 2-year longitudinal study, the Vape shop Advertising, Place characteristics and Effects Surveillance (VAPES) study. VAPES examines the vape retail environment and its impacts on young-adult e-cigarette and other substance use. This study recruited participants from six US metropolitan statistical areas (MSAs; Atlanta, Boston, Minneapolis, Oklahoma City, San Diego and Seattle) representing different tobacco control policies [29] and different policies with respect to legal CBD product sales (as of 2020 when survey data were collected) [30]. This study, detailed elsewhere [31], was approved by the Institutional Review Boards of [omitted for blind review].
Potential participants were recruited via ads on social media (Facebook and Reddit) in Fall 2018. Eligibility criteria were (i) 18–34 years old; (ii) residing in the six aforementioned MSAs and (iii) English speaking. After clicking an ad, individuals were directed to a webpage with a consent form, completed an online eligibility screener and then completed the online baseline survey. Participants were notified that, 7 days later, they would receive an email to confirm their participation. Upon confirming, they were officially enrolled and emailed their first incentive ($10 e-gift card). Purposive, quota-based sampling was used to ensure sufficient proportions of e-cigarette and cigarette users and to obtain roughly equal numbers of men and women and 40% racial/ethnic minority; subgroup enrollment was capped by MSA. Of 10 433 who clicked on ads, 9847 consented, of which 2751 (27.9%) were not allowed to advance due to (a) ineligibility (n = 1472) and/or (b) their subgroup target being met (n = 1279). Of those allowed to advance, 48.8% (3460/7096) provided complete data and 3006 (86.9%) confirmed participation at the 7-day follow-up.
Quantitative measures
Current analyses used baseline sociodemographic and Wave 5 (W5) data (n = 2476, 82.4% retention), which was collected in October–December 2020. Analyses were restricted to those who completed the assessment of ever/lifetime CBD use (n = 2464 total, excluding 12 who reported ‘prefer not to answer’).
Sociodemographics
Baseline measures assessed: age, sex, sexual orientation, race, ethnicity and education. MSA of residence at W5 was also included.
CBD information sources
Participants were asked, ‘Where did you first learn about CBD? friends/family; products/ads at convenience store, grocery store and/or gas station; CBD-related content/ads online (e.g. online advertisements or ads shared via social media); social media postings; CBD stores; healthcare provider; fliers, ads, promotions, etc. in print media (newspapers, magazines); TV; radio; other; have not heard of CBD’ [20, 32].
CBD knowledge
Participants were asked to indicate ‘true’ or ‘false’ (or ‘don’t know’) to the following statements: ‘CBD can get you “high”’; ‘CBD, hemp, and marijuana are all the same’ and ‘CBD products are required to be: (i) tested and proven safe in order to be sold to consumers; (ii) approved by the Food and Drug Administration (FDA) in order to be sold to consumers; and (iii) proven to be effective in order to be marketed for pain relief, anxiety reduction, sleep, etc.’ [10, 18, 32].
CBD perceptions
Participants were asked the following questions (1 = not at all to 7 = extremely): ‘How addictive do you think using CBD is? How harmful to your health do you think using CBD is? How socially acceptable among your peers do you think using CBD is?’ Using the same response options, they were also asked to respond to: ‘CBD is effective in: (i) relieving pain; (ii) reducing anxiety; (iii) helping people sleep; and (iv) therapy for epilepsy/seizures’ [10, 18, 32].
CBD use and use intentions
Participants were asked, ‘Have you ever used CBD products?’ Ever users (i.e. those who used at least once in their lifetime) were asked, ‘In the past 6 months, on how many days have you used CBD products?’ These items were used to categorize participants as never versus ever users; ever users were further subcategorized as past 6-month users versus those not using in the past 6 months. Participants were asked the following questions (1 = not at all to 7 = extremely): ‘How likely are you to try or continue to use CBD products in the next year?’ [32].
Data analysis
Descriptive analyses were conducted to characterize the overall sample. Bivariate analyses were then conducted to characterize CBD never users versus ever users who had not used in the past 6 months versus past 6-month users in relation to sociodemographics and CBD information sources, knowledge, perceptions and use intentions. Analyses were conducted in Stata SE v16, and alpha was set at 0.05.
Qualitative data collection
In February–April 2021, past 30-day e-cigarette users identified at W5 were recruited via email to participate in semi-structured interviews (as the interviews focused on e-cigarette use broadly, with CBD being a component of the interviews). The Consolidated Criteria for Reporting Qualitative Research guidelines were used to guide the qualitative research [33]. Quota-based sampling was used to achieve a sample with representation across the sexes, sexual orientation and racial/ethnic backgrounds. Of the 139 participants recruited via email, 105 (75.5%) began the eligibility screener, of whom 11 (10.5%) only partially completed it and 94 (89.5%) completed it. Of the 94, 34 (36.2%) were not eligible (i.e. not past 30-day e-cigarette users) and 60 (63.8%) were eligible and consented. Of the 60, 40 (66.7%) were successfully scheduled for and participated in an interview, at which point saturation had been reached.
The semi-structured interview guide was developed by the study team, based on the existing evidence base [6, 10, 18, 20] and preliminary survey data, to explore experiences with tobacco and cannabis product use. The initial interview guide was piloted for phrasing, clarity and necessary probes through mock interviews among four graduate research assistants and then revised after the first three interviews were conducted to ensure clarity and comprehensiveness. The current paper focused on interview questions regarding CBD. This section began by asking, ‘CBD is commonly found in vape shops, but people know very little about the product. Do you know what CBD is? If so, how did you learn about it? What do you know about CBD? How do you think it differs from marijuana?’ If participants reported no or little knowledge about CBD, they were provided information: ‘As you may or may not know, CBD – or cannabidiol – is part of the cannabis plant which is made up of CBD and THC. CBD is the non-psychoactive portion of the plant. CBD products come in various forms – for example, in foods, lotions, or vaped liquids. They are marketed for use for various purposes – for example, anxiety, pain, movement disorders – but the scientific evidence is limited. Given this information, tell me what you think about CBD?’ Participants were then asked: (i) ‘What do you find appealing about CBD? (ii) What concerns do you have regarding CBD use? (iii) How do you think it compares to marijuana? (iv) Would you try CBD? Why or why not? (v) Have you used CBD? Why? Where did you get it? What did you think?’
Interviews were conducted via Webex by four female graduate research assistants trained in qualitative data collection, digitally recorded and lasted about 45 min. Participants were debriefed and compensated with a $35 Amazon e-gift card following completion of the interview. Digitally recorded interviews were uploaded to a secure, password-protected computer and transcribed verbatim by a professional transcription service.
Data analysis
Qualitative data were analyzed using QRS Software NVivo v12 and thematic analyses. Transcripts were systematically coded using NVivo and cross-checked for agreement about the application of the codes. Team discussions took place regularly where the codebook themes were re-defined, inclusion and exclusion criteria set and representative passages identified. Discrepancies regarding code choices were resolved through discussion in a process of constant comparison and until consensus was reached (Kappa = 93.3%). Inter-rater reliability was calculated for each code through the use of an intra-class correlation coefficient and was deemed acceptable if the coefficient was ≥0.80. Content codes were used to thematically group similar interview text; themes were organized into overarching domains compiled with representative quotations, which were edited for readability. Balancing the controversy in qualitative research regarding whether to quantify qualitative results, the frequency with which participants reported themes were indicated by ‘quantitizing’ them as ‘most’, ‘many’, ‘almost half’, ‘some’ and ‘a few’ [34, 35]. Additionally, descriptive statistics were conducted to characterize the qualitative study sample, using SPSS 24.0.
Results
Quantitative results
Table I presents quantitative findings from the survey data (N = 2464). Participants were an average age of 24.67 years old, 57.4% female, 68.9% heterosexual, 28.7% racial minority and 11.0% Hispanic. Overall, 51.4% reported ever using CBD, and 32.0% were past 6-month users. Only 2.1% had never heard of CBD. The greatest proportion of participants had learned about CBD from friends/family members (58.9%), followed by products/ads at retail stores (36.4%), online content/ads (34.8%), exposure to CBD stores (27.5%) and social media (26.7%). While few participants believed that CBD could get one ‘high’ (9.8%) or that CBD, hemp and marijuana were the same (6.3%), roughly a quarter of participants indicated ‘true’ to CBD products are required to be ‘approved by FDA to be sold to consumers’ (24.9%), ‘tested/proven safe to be sold to consumers’ (28.8%) and ‘proven effective to be marketed for pain relief, anxiety reduction, sleep, etc.’ (27.2%). As shown in Fig. 1, participant means indicated low average perceived risk (addictiveness: M = 2.34 [SD = 1.64], harm to health: M = 2.30 [SD = 1.62]; scale: 1–7) and high perceived social acceptability (M = 5.87 [SD = 1.62]) and effectiveness for pain, anxiety, sleep and epilepsy/seizures (M values > 4.5). The mean regarding use intentions was 3.17 (SD = 2.18, scale: 1–7).
Table I.
Participant characteristics overall and across never users, ever but not past 6-month users and past 6-month CBD users
Overall N = 2464 (100.0%) |
Never usea N = 1198 (48.6%) |
Ever but not past 6-month use N = 477 (19.4%) |
Past 6-month use N = 789 (32.0%) |
||
---|---|---|---|---|---|
Variables |
N (%) or M (SD) |
N (%) or M (SD) |
N (%) or M (SD) |
N (%) or M (SD) |
P |
Sociodemographics | |||||
MSA, N (%) | <0.001 | ||||
Atlanta metro area | 382 (15.5) | 207 (17.3) | 67 (14.1) | 108 (13.7) | |
Boston metro area | 326 (13.2) | 175 (14.5) | 63 (13.2) | 89 (11.3) | |
Minneapolis metro area | 343 (13.9) | 154 (15.5) | 74 (15.5) | 114 (14.6) | |
Oklahoma City metro area | 153 (6.2) | 83 (6.9) | 25 (5.2) | 45 (5.7) | |
San Diego metro area | 365 (14.8) | 170 (14.2) | 66 (13.8) | 129 (16.4) | |
Seattle metro area | 312 (12.7) | 125 (10.4) | 53 (11.1) | 134 (17.0) | |
Otherb | 583 (23.7) | 285 (23.8) | 129 (27.0) | 169 (21.4) | |
Age (M, SD) | 24.67 (4.69) | 24.28 (4.67) | 24.51 (4.57) | 25.35 (4.71) | <0.001 |
Female, N (%)c | 1374 (57.4) | 618 (52.8) | 281 (61.0) | 475 (62.3) | <0.001 |
Sexual minority, N (%) | 766 (31.1) | 312 (26.0) | 174 (36.5) | 280 (35.5) | <0.001 |
Race, N (%) | <0.001 | ||||
White | 1756 (71.3) | 809 (67.5) | 363 (76.1) | 584 (74.0) | |
Black | 133 (5.4) | 77 (6.4) | 17 (3.6) | 39 (4.9) | |
Asian | 315 (12.8) | 206 (17.2) | 44 (9.2) | 65 (8.2) | |
Other | 260 (10.6) | 106 (8.9) | 53 (11.1) | 101 (12.8) | |
Hispanic, N (%) | 272 (11.0) | 145 (12.1) | 39 (8.2) | 88 (11.2) | 0.068 |
Education ≥Bachelor’s degree, N (%) | 1860 (75.5) | 936 (78.1) | 356 (74.6) | 568 (72.0) | 0.007 |
P-values reflect omnibus tests of differences across three subgroups (i.e. never, ever/not past 6 months and past 6-month users).
n = 73 ‘don’t know’ to ‘Have you ever used CBD?’ recoded as ‘never users’.
Moved since baseline.
n = 69 chose ‘other’.
Fig. 1.
Key perceptions and beliefs regarding CBD among US young adults.
^Scale of 1 = not at all to 7 = extremely. Standard deviations range from 1.62 (harmfulness to health, social acceptability) to 1.78 (for therapy for epilepsy/seizures).
Bivariate analyses indicated differences across never, ever (but not past 6 month) and past 6-month users with respect to age, sex, sexual orientation, race and education (see footnote in Table I for details). As shown in Table II, those most misinformed (i.e. those providing inaccurate [‘true’] or ‘don’t know’ responses) to the CBD knowledge items were never users and past 6-month users (P-values < 0.01). Never users reported the lowest CBD use intentions, while past 6-month users reported the highest (P < 0.001). In terms of perceptions, never users perceived CBD least favorably (i.e. most addictive and harmful to health, least socially acceptable and effective for treating health issues), with past 6-month users perceiving CBD the most favorably across these dimensions (P-values < 0.001).
Table II.
CBD-related characteristics overall and across never users, ever but not past 6-month users and past 6-month CBD users
Overall N = 2464 (100.0%) | Never usea N = 1198 (48.6%) | Ever but not past 6-month use N = 477 (19.4%) | Past 6-month use N = 789 (32.0%) | ||
---|---|---|---|---|---|
Variables | N (%) or M (SD) | N (%) or M (SD) | N (%) or M (SD) | N (%) or M (SD) | P |
CBD-related characteristics | |||||
How first learned about CBD, N (%) ∼ | |||||
From friends/family members | 1451 (58.9) | 637 (53.2) | 318 (66.7) | 496 (62.9) | <0.001 |
Products/ads at retail stores | 897 (36.4) | 486 (40.6) | 171 (35.9) | 240 (30.4) | <0.001 |
Content/ads online | 858 (34.8) | 451 (37.6) | 150 (31.5) | 257 (32.6) | 0.015 |
Exposure to CBD stores | 678 (27.5) | 347 (29.0) | 122 (25.6) | 209 (26.5) | 0.276 |
Social media postings | 659 (26.7) | 329 (27.5) | 118 (24.7) | 212 (26.9) | 0.522 |
TV | 261 (10.6) | 143 (11.9) | 47 (9.9) | 71 (9.0) | 0.096 |
Fliers, ads, promotions, etc. in print media | 235 (9.5) | 117 (9.8) | 49 (10.3) | 69 (8.8) | 0.623 |
Radio | 160 (6.5) | 95 (7.9) | 24 (5.0) | 41 (5.2) | 0.019 |
Healthcare provider | 152 (6.2) | 52 (4.3) | 22 (4.6) | 78 (9.9) | <0.001 |
Other | 191 (7.8) | 65 (5.4) | 41 (8.6) | 85 (10.8) | <0.001 |
Never heard of CBD | 52 (2.1) | 52 (4.3) | 0 (0.0) | 0 (0.0) | n/a |
CBD knowledge; indicated ‘true’ to: N (%)b | |||||
CBD can get you ‘high’ | 241 (9.8) | 159 (13.3) | 32 (6.7) | 50 (6.3) | <0.001 |
CBD, hemp and marijuana are same | 154 (6.3) | 105 (8.8) | 13 (2.7) | 36 (4.6) | <0.001 |
CBD products must be: | |||||
Approved by FDA to be sold to consumers | 613 (24.9) | 309 (25.8) | 111 (23.3) | 193 (24.5) | <0.001 |
Tested/proven safe to be sold to consumers | 710 (28.8) | 343 (28.6) | 129 (27.0) | 238 (30.2) | 0.002 |
Proven effective to be marketed for pain relief, anxiety reduction, sleep, etc. | 670 (27.2) | 323 (27.0) | 121 (25.4) | 226 (28.6) | 0.004 |
CBD use intentions (next year), M (SD)c | 3.17 (2.18) | 1.99 (1.46) | 2.83 (1.78) | 5.17 (1.88) | <0.001 |
P-values reflect omnibus tests of differences across three subgroups (i.e. never, ever/not past 6 months and past 6-month users).
n = 73 ‘don’t know’ to ‘Have you ever used CBD?’ recoded as ‘never users’.
‘Don’t know’ responses were 376 (15.3%), 241 (9.8%), 931 (37.8%), 866 (35.2%) and 796 (32.3%), respectively.
Scale of 1 = not at all to 7 = extremely.
Qualitative results
Interview participants (N = 40) were from across MSAs (range: 3 [7.5%] in Oklahoma City to 10 [25.0%] in Minneapolis-St. Paul), were an average age of 26.30 years (SD = 4.39), 35.0% (n = 14) female, 45.0% (n = 18) sexual minority, 57.5% (n = 23) White, 5.0% (n = 2) Black, 22.5% (n = 9) Asian, 15.0% (n = 6) other race, 12.5% (n = 5) Hispanic and 75.0% (n = 30) educated at least the Bachelor’s degree level (not shown in tables). Overall, 27.5% (n = 11) reported past 30-day CBD use and 45.0% (n = 18) reported past 30-day cannabis use.
Health benefits of CBD
Table III provides themes, subthemes and representative quotations from the qualitative interviews. There was wide variability in terms of participants’ general knowledge about CBD. Regarding health benefits, many participants noted CBD’s usefulness for anxiety, sleep and pain. Some participants indicated that CBD might be better as a ‘natural’ or ‘holistic’ approach to treat anxiety compared with a more medicated treatment. Some participants also indicated the potential for CBD to aid with sleep due to its calming effect and to alleviate pain. In addition, some participants indicated that CBD products provided the health benefits of medicinal cannabis without psychoactive effects.
Table III.
Participants describe the health aspects and knowledge of CBD
Theme and subtheme | Representative quotation |
---|---|
General knowledge |
|
Health benefits | |
Anxiety and sleep |
|
Pain |
|
Benefits of medicinal cannabis without psychoactive effects |
|
Concerns about CBD use | |
Implications of THC in CBD products; too close to cannabis |
|
Potential for addiction or overuse |
|
Lack of research or scientific evidence |
|
Lack of regulation |
|
Cost |
|
CBD marketing exposure | |
High levels of marketing exposure |
|
Online marketing |
|
Personal experiences using CBD | |
Methods of use | |
Vaping |
|
Smoking |
|
Tinctures |
|
Topicals |
|
Product source | |
Retailers |
|
Online |
|
Friends, family and others in social network |
|
Personal effects of CBD | |
Limited effects |
|
|
|
Effects for anxiety, sleep |
|
Effects for pain relief |
|
Negative experiences |
|
Concerns about CBD use
Some participants expressed concerns of CBD being too closely related to cannabis and thus the potential for CBD use to lead to cannabis use. Additionally, some participants noted concerns regarding the potential of CBD addiction and/or overdose. Many were concerned by the lack of research or scientific evidence regarding the utility or consequences of CBD use. For example, one participant commented on the implications of people relying on CBD use for symptom management despite no clinical evidence base, but another commented that they felt that one should be able to freely try CBD products for symptom management if they so choose. Others noted concerns regarding the limited regulation of CBD. Relatedly, some reported specifically the concern that there is no real way to know what is in a specific CBD product or how much or little should be used. Lastly, participants discussed CBD as being costly. This was also linked to concerns about limited regulation and whether there was an evidence base regarding its effectiveness for certain conditions.
Marketing exposure
Some participants noted relatively high levels of marketing exposure. Some commented that the marketing they had seen largely focused on health benefits—particularly for anxiety, epilepsy and pain—and that product novelty was highlighted frequently. Prominent sources of marketing exposure were online, particularly via social media and in large online retailers (e.g. Amazon).
Personal experiences with CBD use
Participants reported various modes of use and sources of CBD products. A few reported vaping CBD e-liquid, smoking it via flour or CBD cigarettes, using tinctures such as liquid drops under the tongue or as topicals (e.g. lotions, particularly for pain). Participants indicated different sources of CBD. For example, a few indicated tobacco retailers (i.e. vape or smoke shops), online retailers and via friends, family and others in their social network.
In terms of effects of CBD use that participants experienced, most participants indicated limited effects of CBD. Some noted that the effects they experienced were possibly more of a placebo effect. Some noted that, despite their own experiences, they knew of others who experienced benefits of CBD use. Several participants indicated positive personal experiences with CBD for anxiety, sleep and pain relief. Few participants reported any negative experiences resulting from CBD use. For example, one participant noted an experience where CBD use made them feel ‘stoned’, perhaps due to using a potentially tainted product.
Discussion
This study is among the few that have examined CBD-related knowledge, perceptions, use and use intentions among young adults in the United States [8–10]. Among survey participants, almost all had heard of CBD, over half had ever used CBD products and a third used CBD products in the past 6 months. The majority (58.9%) of survey participants reported first learning about CBD from friends/family, with roughly a third learning about it at retailers or online (respectively), which is consistent with prior literature [6, 11–14]. Interview participants elaborated on these points and also indicated that social media and other online advertisements played salient roles, perhaps because FDA does not regulate social media advertisement [21]. Similarly, previous research found the internet and informal sources were predominately where consumers learn about CBD (rather than from a physician, for example) [6, 20].
Participants generally held positive perceptions of CBD. On average, young adults in this study perceived CBD as safe to use and effective for addressing pain, anxiety and sleep. Interview participants indicated that it is a more ‘holistic’ and ‘natural’ remedy for headaches, anxiety, pain and sleep, despite the fact that the FDA does not approve of CBD as a dietary supplement and the limited available evidence regarding the effectiveness of CBD as a treatment for such conditions, as noted in prior research [6, 23]. Moreover, bivariate analyses of the survey data indicated that more favorable perceptions of CBD correlated with lifetime and past 6-month use, as well as greater use intentions among never users, aligning with numerous health behavior theories that suggest that behavior is predicted by such perceptions of risks and benefits [36–38]. However, most interview participants noted that CBD produced limited effects and, fortunately, few reported any negative effects of CBD use, contrary to prior research indicating that over half of CBD users experienced at least one unexpected side effect [10, 20]. Notably, roughly a quarter of survey participants falsely believed that CBD products were required to be approved by FDA to be sold to consumers, proven safe to be sold to consumers and confirmed effective to be marketed for pain relief, anxiety reduction, sleep, etc. (respectively). In general, these findings add to the literature that suggest confusion about the legality and regulation of CBD, confounded by the limited and evolving regulation and manufacturing guidelines [10, 39]. However, it is encouraging that some interview participants indicated that prominent concerns included limited regulation and/or evidence regarding CBD’s effectiveness or risks and that roughly 35–40% of survey participants were knowledgeable about CBD regulatory oversight.
Findings from this study have implications for research and practice. This study found that young-adult CBD use correlated with positive perceptions of CBD and that young adults generally perceived CBD positively, believed in its effectiveness in treating certain conditions (e.g. sleep, anxiety and pain) and largely learned about and obtained CBD via social networks, retailers and online. Importantly, roughly a quarter of survey participants held untrue beliefs regarding FDA’s regulatory oversight of CBD products and marketing, and interview participants indicated concerns about limited CBD’s evidence base and regulatory oversight. Collectively, these findings underscore for both research and regulators to monitor CBD retail and marketing (e.g. via website audits and brick-and-mortar store audits) and their impact on consumer perceptions and behavior, particularly as the market expands and policies evolve to further regulate CBD [25]. Furthermore, practitioners should consider taking measures to explicitly address retail claims regarding CBD’s effects in order to prevent the spread of misinformation and/or misleading information to consumers.
Study strengths and limitations
This study is strengthened by a large diverse sample of young adults living in six distinct US MSAs and a rigorous mixed-methods design providing in-depth data regarding CBD perceptions. Study limitations include limited generalizability to other US young adults, given that this sample was drawn from six MSAs using purposive sampling to obtain target sample sizes of e-cigarette and cigarette users. Second, interview participants who were unfamiliar with CBD were provided with information about CBD, and most survey participants were exposed to CBD descriptions in the 2019 survey. These exposures may have impacted their awareness—and potentially use—of CBD. Lastly, assessments were self-reported (thus subject to recall bias [40]), and the data analyzed were cross-sectional, limiting the ability to determine causal associations.
Conclusions
Given CBD’s growing popularity and marketing expansion advertising wide-ranging health benefits, this is a pivotal time for surveillance of perceptions and use of CBD, particularly among young adults. Young-adult participants in this study generally perceived CBD as safe and effective for treating various health conditions and had limited knowledge regarding CBD product regulation. These findings are concerning and further underscored by the limited regulation and clinical evidence regarding CBD’s effectiveness in treating various health conditions, particularly those for which it is commonly marketed. Such gaps in the regulation of the CBD market and in consumer education leave vulnerable populations, such as young adults, at risk for uptake.
Acknowledgements
None declared.
Contributor Information
Christina N Wysota, Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, 950 New Hampshire Ave. NW, Washington, DC, USA.
Daisy Le, Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, 950 New Hampshire Ave. NW, Washington, DC, USA; Department of Policy, Populations, and Systems, School of Nursing, George Washington University, 1919 Pennsylvania Ave. NW, Washington, DC 20006, USA; George Washington Cancer Center, George Washington University, 800 22nd St. NW, Washington, DC, USA.
Michelle Elise Clausen, Department of Policy, Populations, and Systems, School of Nursing, George Washington University, 1919 Pennsylvania Ave. NW, Washington, DC 20006, USA.
Annie Coriolan Ciceron, Department of Policy, Populations, and Systems, School of Nursing, George Washington University, 1919 Pennsylvania Ave. NW, Washington, DC 20006, USA.
Caroline Fuss, Department of Global Health, Milken Institute School of Public Health, George Washington University, 950 New Hampshire Ave. NW, Washington, DC 20052, USA.
Breesa Bennett, Department of Epidemiology, Milken Institute School of Public Health, George Washington University, 950 New Hampshire Ave. NW, Washington, DC 20052, USA.
Katelyn F Romm, Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, 950 New Hampshire Ave. NW, Washington, DC, USA.
Zongshuan Duan, Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, 950 New Hampshire Ave. NW, Washington, DC, USA.
Carla J Berg, Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, 950 New Hampshire Ave. NW, Washington, DC, USA; George Washington Cancer Center, George Washington University, 800 22nd St. NW, Washington, DC, USA.
Funding
This work was supported by the US National Cancer Institute (R01CA215155-01A1; Principal Investigator [PI]: Berg). Dr. Berg is also supported by other US National Institutes of Health funding, including the National Cancer Institute (R01CA239178-01A1; Multiple Principal Investigators [MPIs]: Berg, Levine; R01CA179422-01; PI: Berg; R21 CA261884-01A1; MPIs: Berg, Arem), the Fogarty International Center (R01TW010664-01; MPIs: Berg, Kegler), the National Institute of Environmental Health Sciences/Fogarty (D43ES030927-01; MPIs: Berg, Caudle, Sturua), and the National Institute on Drug Abuse (R01DA054751-01A1; MPIs: Berg, Cavazos-Rehg). Dr. Romm is supported by the National Institute on Drug Abuse (F32DA055388-01; PI: Romm; R25DA054015; MPIs: Obasi, Reitzel).
Conflict of interest statement
None declared.
References
- 1. Federal Registrar . Denial of petition to initiate proceedings to reschedule marijuana. Fed Regist 2016; 8: 131. [Google Scholar]
- 2. Drug Enforcement Administration, Department of Justice . Establishment of a new drug code for marihuana extract final rule. Fed Regist 2016; 81: 90194–6. [PubMed] [Google Scholar]
- 3. Kight on Cannabis . Is CBD Illegal Under the new DEA ‘Marihuana Extract’ rule? A Legal Analysis. 2018. Available at: https://cannabusiness.law/is-cbd-illegal-under-the-new-dea-marihuana-extract-rule-a-legal-analysis/. Accessed: 15 March 2022.
- 4. Wallace A. CBD product sales are booming, in Now the FDA Needs to Weigh in. CNN Business. 2019.
- 5. Leas EC et al. Trends in internet searches for cannabidiol (CBD) in the United States. JAMA Network Open 2019; 2: e1913853. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Goodman S et al. Use and perceptions of cannabidiol products in Canada and in the United States. Cannabis Cannabinoid Res 2020; 7: 355–64. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Food and Drug Administration . FDA and Marijuana: Questions and Answers. Available at: https://www.fda.gov/newsevents/publichealthfocus/ucm421168.htm. Accessed: 5 December 2019. p. 04–21.
- 8. Gill L. CBD goes mainstream. Consumer Reports. 2019.
- 9. Brenan M. 14% of Americans Say They Use CBD Products. Available at: https://news.gallup.con.poll/263147/americans-say-cbd-products-aspx. Published 7 August 2019; Accessed: 22 March 2020.
- 10. Wheeler M et al. CBD (cannabidiol) product attitudes, knowledge, and use among young adults. Subst Use Misuse 2020; 55: 1138–45. [DOI] [PubMed] [Google Scholar]
- 11. Food and Drug Administration . FDA Regulation of Cannabis and Cannabis-Derived Products: Questions and Answers. Available at: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd. Accessed: 2 April 2019.
- 12. Brown JD, Winterstein AG. Potential adverse drug events and drug–drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med 2019; 8: 989. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Levinsohn EA, Hill KP. Clinical uses of cannabis and cannabinoids in the United States. J Neurol Sci 2020; 411: 116717. [DOI] [PubMed] [Google Scholar]
- 14. Reiley L. CBD-infused food and beverages are still illegal under US law. So why are they everywhere? The Washington Post. 2019. 2020.
- 15. Spindle TR et al. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Drug Alcohol Depend 2020; 211: 107937. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. McGregor IS et al. Access to cannabidiol without a prescription: a cross-country comparison and analysis. Int J Drug Policy 2020; 85: 102935. [DOI] [PubMed] [Google Scholar]
- 17. Spindle TR, Bonn-Miller BO, Vandrey R. Changing landscape of cannabis: novel products, formulations, and methods of administration. Curr Opin Psychol 2019; 30: 98–102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Moltke J, Hindocha C. Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. J Cannabis Res 2021; 3: 5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Berg CJ et al. Vape shop owners’/managers’ attitudes about CBD, THC, and marijuana legal markets. Prev Med Rep 2020; 20: 101208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Corroon J, Phillips JA. A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res 2018; 3: 152–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Merten JW et al. Cannabidiol (CBD): perspectives from Pinterest. Subst Use Misuse 2020; 55: 2213–20. [DOI] [PubMed] [Google Scholar]
- 22. Wise J. FDA approves its first cannabis based medicine. BMJ 2018; 361: k2827. [DOI] [PubMed] [Google Scholar]
- 23. Millar SA et al. A systematic review of cannabidiol dosing in clinical populations. Br J Clin Pharmacol 2019; 85: 1888–900. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Larsen C, Shahinas J. Dosage, efficacy and safety of cannabidiol administration in adults: a systematic review of human trials. J Clin Med Res 2020; 12: 129–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Cass D. High Hopes for FDA Regulation of CBD Products. The Regulatory Review, 2021. Available at: https://www.theregreview.org/2021/12/16/cass-high-hopes-fda-regulation-cbd-products/. Accessed: 3 May 2022. [Google Scholar]
- 26. US Senate . Hemp Access and Consumer Safety Act. 2021. Available at: https://www.wyden.senate.gov/imo/media/doc/Hemp%20Access%20and%20Consumer%20Safety%20Act%20of%202021%20One%20Pager.pdf. Accessed: 19 January 2022.
- 27. US Senate . The Cannabis Administration and Opportunity Act. 2021. Available at: https://www.democrats.senate.gov/imo/media/doc/CAOA%20Detailed%20Summary%20-.pdf. Accessed: 19 January 2022.
- 28. US House of Representatives . Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act. 2021. Available at: https://schrader.house.gov/newsroom/documentsingle.aspx?DocumentID=392857. Accessed: 19 January 2022.
- 29. Public Health Law Center . Commercial Tobacco and Marijuana. 2020. Available at: https://www.publichealthlawcenter.org/topics/commercial-tobacco-control/commercial-tobacco-and-marijuana. Accessed: 25 March 2022.
- 30. Vonder Haar M. Update: A State-by-State Breakdown of CBD Laws. 2020. Available at: https://www.cspdailynews.com/cbdhemp/update-state-state-breakdown-cbd-laws. Accessed: 19 January 2022.
- 31. Berg CJ et al. Young adult e-cigarette use and retail exposure in 6 US metropolitan areas. Tob Reg Sci 2021; 7: 59–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Wysota CN et al. CBD knowledge, perceptions and use among young adults in 6 US metropolitan areas. Cannabis Cannabinoid Res 2022. 10.1089/can.2022.0029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 2007; 19: 349–57. [DOI] [PubMed] [Google Scholar]
- 34. Sandelowski M, Voils CI, Knafl G. On quantitizing. J Mix Methods Res 2009; 3: 208–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Eval Academy . How to ‘Quantify’ Qualitative Data. Available at: https://www.evalacademy.com/articles/how-to-quantify-qualitative-data. Accessed: 1 May 2022.
- 36. Bandura A. Social cognitive theory: an agentic perspective. Annu Rev Psychol 2001; 52: 1–26. [DOI] [PubMed] [Google Scholar]
- 37. Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Process 1991; 50: 179–211. [Google Scholar]
- 38. Janz NK, Becker MH. The health belief model: a decade later. Health Educ Q 1984; 11: 1–47. [DOI] [PubMed] [Google Scholar]
- 39. Bhamra SK et al. The emerging role of cannabidiol (CBD) products; a survey exploring the public’s use and perceptions of CBD. Phytotherapy Res 2021; 35: 5734–40. [DOI] [PubMed] [Google Scholar]
- 40. Coughlin SS. Recall bias in epidemiologic studies. J Clin Epidemiol 1990; 43: 87–91. [DOI] [PubMed] [Google Scholar]